GlassScriptPhysician profile
Harris M Kenner
NPI 1558368464
$3,126.45
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $706 · 2021: $569 · 2022: $280.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $391.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.92 | 2019-2022 | |
| Pfizer INC. | $275.03 | 2019-2022 | |
| Daiichi Sankyo INC. | $264.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $217.50 | 2019-2022 | |
| Amarin Pharma, INC. | $206.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $179.87 | 2019-2021 | |
| Abbott Laboratories | $124.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.15 | 2021-2022 | |
| Boston Scientific Corporation | $61.52 | 2019 | |
| Esperion Therapeutics, INC. | $61.38 | 2020-2021 | |
| Lundbeck LLC | $56.16 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $46.93 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.76 | 2020-2021 | |
| Astellas Pharma US INC | $40.26 | 2019-2021 | |
| Novo Nordisk INC | $35.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.00 | 2020 | |
| Tactile Systems Technology INC | $22.74 | 2019 | |
| Ibsa Pharma INC. | $20.28 | 2021 | |
| Edwards Lifesciences Corporation | $18.11 | 2022 | |
| Horizon Therapeutics Plc | $16.20 | 2019 | |
| Gilead Sciences, INC. | $14.23 | 2019 | |
| Bardy Diagnostics, INC. | $13.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.00 | 2021 | |
| Allergan, INC. | $11.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harris Kenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.